A class action lawsuit has been filed against Baxter International Inc. on behalf of investors who suffered losses between February 23, 2022, and October 29, 2025, due to alleged securities fraud. The complaint claims that Baxter made false statements and concealed significant defects in its Novum LVP product, which reportedly caused widespread malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, putting patients at risk of serious injury or death. It is alleged that Baxter was aware of multiple device failures, injuries, and deaths, and that the company's efforts to address these issues were inadequate. The suit contends that Baxter misrepresented the safety, performance, and sales prospects of the Novum LVP, which may have led to increased risks for investors and patients alike.